Premium
Secondary prevention measures in anaphylaxis patients: Data from the anaphylaxis registry
Author(s) -
Kraft Magdalena,
Knop Macarena Pia,
Renaudin JeanMarie,
Scherer Hofmeier Kathrin,
Pföhler Claudia,
Bilò Maria Beatrice,
Lang Roland,
Treudler Regina,
Wagner Nicola,
Spindler Thomas,
Hourihane Jonathan O'B,
Maris Ioana,
Koehli Alice,
Bauer Andrea,
Lange Lars,
Müller Sabine,
Papadopoulos Nikolaos G.,
Wedi Bettina,
Moeser Anne,
Ensina Luis F.,
FernandezRivas Montserrat,
CichockaJarosz Ewa,
Christoff George,
Garcia Blanca E.,
PoziomkowskaGęsicka Iwona,
Cardona Victoria,
Mustakov Tihomir B.,
Rabe Uta,
Mahler Vera,
Grabenhenrich Linus,
DölleBierke Sabine,
Worm Margitta
Publication year - 2020
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1111/all.14069
Subject(s) - anaphylaxis , medicine , guideline , allergy , reimbursement , comorbidity , secondary prevention , secondary care , family medicine , emergency medicine , health care , primary care , immunology , pathology , economics , economic growth
Background Patients with a history of anaphylaxis are at risk of future anaphylactic reactions. Thus, secondary prevention measures are recommended for these patients to prevent or attenuate the next reaction. Methods Data from the Anaphylaxis Registry were analyzed to identify secondary prevention measures offered to patients who experienced anaphylaxis. Our analysis included 7788 cases from 10 European countries and Brazil. Results The secondary prevention measures offered varied across the elicitors. A remarkable discrepancy was observed between prevention measures offered in specialized allergy centers (84% of patients were prescribed adrenaline autoinjectors following EAACI guidelines) and outside the centers: Here, EAACI guideline adherence was only 37%. In the multivariate analysis, the elicitor of the reaction, age of the patient, mastocytosis as comorbidity, severity of the reaction, and reimbursement/availability of the autoinjector influence physician's decision to prescribe one. Conclusions Based on the low implementation of guidelines concerning secondary prevention measures outside of specialized allergy centers, our findings highlight the importance of these specialized centers and the requirement of better education for primary healthcare and emergency physicians.